310 related articles for article (PubMed ID: 19234176)
1. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells.
Parekh VV; Lalani S; Kim S; Halder R; Azuma M; Yagita H; Kumar V; Wu L; Kaer LV
J Immunol; 2009 Mar; 182(5):2816-26. PubMed ID: 19234176
[TBL] [Abstract][Full Text] [Related]
2. Cutting edge: Programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy.
Chang WS; Kim JY; Kim YJ; Kim YS; Lee JM; Azuma M; Yagita H; Kang CY
J Immunol; 2008 Nov; 181(10):6707-10. PubMed ID: 18981087
[TBL] [Abstract][Full Text] [Related]
3. Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model.
Durgan K; Ali M; Warner P; Latchman YE
Cancer Immunol Immunother; 2011 Apr; 60(4):547-58. PubMed ID: 21240487
[TBL] [Abstract][Full Text] [Related]
4. Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus co-stimulation.
Iyoda T; Ushida M; Kimura Y; Minamino K; Hayuka A; Yokohata S; Ehara H; Inaba K
Int Immunol; 2010 Nov; 22(11):905-13. PubMed ID: 21118907
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions.
Akbari O; Stock P; Singh AK; Lombardi V; Lee WL; Freeman GJ; Sharpe AH; Umetsu DT; Dekruyff RH
Mucosal Immunol; 2010 Jan; 3(1):81-91. PubMed ID: 19741598
[TBL] [Abstract][Full Text] [Related]
6. Development of spontaneous anergy in invariant natural killer T cells in a mouse model of dyslipidemia.
Braun NA; Mendez-Fernandez YV; Covarrubias R; Porcelli SA; Savage PB; Yagita H; Van Kaer L; Major AS
Arterioscler Thromb Vasc Biol; 2010 Sep; 30(9):1758-65. PubMed ID: 20539017
[TBL] [Abstract][Full Text] [Related]
7. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy.
Tsushima F; Yao S; Shin T; Flies A; Flies S; Xu H; Tamada K; Pardoll DM; Chen L
Blood; 2007 Jul; 110(1):180-5. PubMed ID: 17289811
[TBL] [Abstract][Full Text] [Related]
8. Ligand-dependent induction of noninflammatory dendritic cells by anergic invariant NKT cells minimizes autoimmune inflammation.
Wang J; Cho S; Ueno A; Cheng L; Xu BY; Desrosiers MD; Shi Y; Yang Y
J Immunol; 2008 Aug; 181(4):2438-45. PubMed ID: 18684934
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of a shorter duration in the state of anergy by an invariant natural killer T cell agonist enhances its efficiency of protection from type 1 diabetes.
Tohn R; Blumenfeld H; Haeryfar SM; Veerapen N; Besra GS; Porcelli SA; Delovitch TL
Clin Exp Immunol; 2011 Apr; 164(1):26-41. PubMed ID: 21361909
[TBL] [Abstract][Full Text] [Related]
10. Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice.
Stirnemann K; Romero JF; Baldi L; Robert B; Cesson V; Besra GS; Zauderer M; Wurm F; Corradin G; Mach JP; Macdonald HR; Donda A
J Clin Invest; 2008 Mar; 118(3):994-1005. PubMed ID: 18259610
[TBL] [Abstract][Full Text] [Related]
11. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.
Hirano F; Kaneko K; Tamura H; Dong H; Wang S; Ichikawa M; Rietz C; Flies DB; Lau JS; Zhu G; Tamada K; Chen L
Cancer Res; 2005 Feb; 65(3):1089-96. PubMed ID: 15705911
[TBL] [Abstract][Full Text] [Related]
12. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ
J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714
[TBL] [Abstract][Full Text] [Related]
13. Brief treatment with iNKT cell ligand α-galactosylceramide confers a long-term protection against lupus.
Yang JQ; Kim PJ; Singh RR
J Clin Immunol; 2012 Feb; 32(1):106-13. PubMed ID: 22002593
[TBL] [Abstract][Full Text] [Related]
14. Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency.
Wingender G; Krebs P; Beutler B; Kronenberg M
J Immunol; 2010 Sep; 185(5):2721-9. PubMed ID: 20660713
[TBL] [Abstract][Full Text] [Related]
15. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
[TBL] [Abstract][Full Text] [Related]
16. PD-1/B7-H1 interaction contribute to the spontaneous acceptance of mouse liver allograft.
Morita M; Fujino M; Jiang G; Kitazawa Y; Xie L; Azuma M; Yagita H; Nagao S; Sugioka A; Kurosawa Y; Takahara S; Fung J; Qian S; Lu L; Li XK
Am J Transplant; 2010 Jan; 10(1):40-6. PubMed ID: 19889124
[TBL] [Abstract][Full Text] [Related]
17. B7-H1-deficiency enhances the potential of tolerogenic dendritic cells by activating CD1d-restricted type II NKT cells.
Brandl C; Ortler S; Herrmann T; Cardell S; Lutz MB; Wiendl H
PLoS One; 2010 May; 5(5):e10800. PubMed ID: 20520738
[TBL] [Abstract][Full Text] [Related]
18. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.
Fife BT; Pauken KE; Eagar TN; Obu T; Wu J; Tang Q; Azuma M; Krummel MF; Bluestone JA
Nat Immunol; 2009 Nov; 10(11):1185-92. PubMed ID: 19783989
[TBL] [Abstract][Full Text] [Related]
19. LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L.
Lucas CL; Workman CJ; Beyaz S; LoCascio S; Zhao G; Vignali DA; Sykes M
Blood; 2011 May; 117(20):5532-40. PubMed ID: 21422469
[TBL] [Abstract][Full Text] [Related]
20. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo.
Sandner SE; Clarkson MR; Salama AD; Sanchez-Fueyo A; Domenig C; Habicht A; Najafian N; Yagita H; Azuma M; Turka LA; Sayegh MH
J Immunol; 2005 Mar; 174(6):3408-15. PubMed ID: 15749874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
